BEDFORD, Mass., & DES PLAINES, Ill.–(BUSINESS WIRE)–September 28, 2017–
Augmenix, Inc., a medical technology company that develops, manufactures and sells proprietary absorbable hydrogels that separate and protect organs at risk during radiotherapy, together with Us TOO International, a nonprofit organization committed to improving the lives of those affected by prostate cancer, will hold a live webcast for prostate cancer patients and their caregivers on Monday, October 2, from 7:15 pm – 9:00 pm EST.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170928005968/en/
SpaceOAR separates the prostate and rectum during radiation treatment (Graphic: Business Wire)
The event will feature a didactic presentation from renowned radiation oncologist Daniel B. Fried, MD, MPH, PhD, who practices at the Gibbs Cancer Center and Research Institute in Greenville, S.C. He will provide relevant clinical information on radiation therapy as a viable treatment for prostate cancer, and discuss the quality of life benefits associated with the utilization of SpaceOAR® Hydrogel as an adjunctive therapy in protecting the rectum in men undergoing this form of treatment. The session will also include an opportunity for webcast attendees to submit questions for Dr. Fried through an online chat.
“More than 160,000 men will be diagnosed with prostate cancer in 2017 and we’re on a mission to help educate those affected so they’re empowered to make informed decisions on all aspects of the disease,” said Chuck Strand, CEO, Us TOO International. “We look forward to partnering with Augmenix on this special educational event. With the company’s support, we are able live stream the content to reach more men and their families throughout the country who are battling prostate cancer.”
The webcast will be live-streamed from an Us TOO support group meeting, which will take place at the Fellowship Greenville Church in Greer, S.C. The event and webcast participation is free of charge to anyone who registers. For registration information, visit bit.ly/2hwEulg. After the group meeting, the webcast recording will be archived for viewing at http://www.ustoo.org/ustoo-video.
“If detected early, prostate cancer is often treatable and knowledge of treatment options can lead to optimal outcomes,” said John Pedersen, CEO, Augmenix. “We are privileged to partner with Us TOO on patient-centric activities that aim to educate, empower and support these men and their families.”
ABOUT AUGMENIX, INC.
Augmenix, Inc. is a privately held U.S. company based in the Boston, Massachusetts area focused on the development and commercialization of radiation oncology products using its proprietary hydrogel technology. Focusing initially on protection during prostate radiation therapy, Augmenix next-generation products will address spacing and marking applications throughout the body to improve radiotherapy and interventional oncology procedure outcomes. The company’s lead product, SpaceOAR System, is FDA cleared and is currently being used in the majority of leading cancer centers in the United States. It is also CE marked, approved in Australia and Japan, and licensed in Canada. SpaceOAR is a registered trademark of Augmenix, Inc. More information about Augmenix and the SpaceOAR hydrogel can be found at http://www.Augmenix.com.
ABOUT SPACEOAR® HYDROGEL
Radiation therapy in the treatment of prostate cancer can cause unintended radiation injury to adjacent healthy tissue (organs at risk). This injury can lead to a range of bowel, urinary and sexual symptoms that can affect patient health and quality of life during radiotherapy, and for years afterward. In recent years, radiation oncologists have considered use of “spacing” techniques to reduce the risk of radiation injury to surrounding tissue during radiotherapy. SpaceOAR hydrogel is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of SpaceOAR hydrogel to reduce the radiation dose delivered to the anterior rectum. The SpaceOAR hydrogel is injected as a liquid into the space between the prostate and rectum where it pushes the structures apart and then solidifies into a soft hydrogel. The hydrogel remains stable for three months during radiation therapy then liquefies and is completely absorbed by the body. See the Instructions for Use for complete information on potential risks, warnings and precautions.
ABOUT US TOO INTERNATIONAL
Us TOO International is a nonprofit that serves the prostate cancer community by providing educational materials and resources at no charge. Established in 1990, the organization was founded by-and continues to be governed by-people directly affected by prostate cancer. The mission of Us TOO is to provide hope and improve the lives of those affected by prostate cancer through support, education and advocacy/awareness. Us TOO currently maintains more than 200 support groups throughout the U.S. and abroad that also help men and their spouses/partners and families make informed decisions about prostate cancer detection, treatment options and related side effects. For more information, visit http://www.ustoo.org/.